What new methods does the FDA recommend for drug testing?

The FDA recommends new approach methodologies (NAMs) such as computer simulations, cell-based tests, and 3D organoid models that mimic human organ functions.

Why is the FDA encouraging a reduction in animal drug studies?

The FDA is encouraging this shift because many experimental drugs passing animal studies still fail in humans, and newer methods are considered more efficient, ethical, and human-relevant.

How can new drug testing methods benefit patients and the industry?

These methods can make drug development more efficient and cheaper, potentially leading to faster market entry, lower research costs, and ultimately, lower drug prices for consumers.

Home / Health / FDA Backs New Drug Testing Methods

FDA Backs New Drug Testing Methods

18 Mar

•

Summary

FDA issues draft guidance to reduce animal drug studies.
New methods include computer simulations and organoids.
Goal is more efficient, cheaper, and ethical drug development.

The U.S. Food and Drug Administration (FDA) released draft guidance on March 18, 2026, aimed at helping companies reduce their reliance on animal testing for experimental drugs. This initiative encourages the adoption of advanced methods, including computer simulations and organ-on-a-chip technologies that mimic human organ functions.

Traditional animal studies, often conducted on primates, have proven insufficient as many candidates that pass these tests still fail in human trials due to safety and efficacy concerns. The FDA's new approach methodologies (NAMs) include cell-based tests and 3D organoid models grown from human cells.